NEW YORK – In a recent study led by researchers at the University of California, Los Angeles, proteomics firm IsoPlexis demonstrated the capabilities of its expanded single-cell analysis platform.
In the work, which was detailed in a paper published last month in Nature Communications, scientists used the company's platform to profile the cytokines produced by both T cells and natural killer (NK) cells in the blood of melanoma patients receiving adoptive cell transfer (ACT) therapy.